Ironwood Pharmaceuticals shares jumped more than 38% after the company issued FY2026 revenue guidance of $450–$475 million, well above expectations. The outlook assumes Linzess sales of $1.125–$1.175 billion, supported by better pricing and steady demand. Linzess was approved last year for pediatric IBS-C, becoming the first treatment of its kind.